|
Revenues
|
|
$78.8m
|
$119.1m
|
$173.5m
|
$235.5m
|
$314.0m
|
$400.4m
|
|
Cost of revenues
|
|
($41.6m)
|
($71.0m)
|
($113.5m)
|
($147.2m)
|
($172.5m)
|
($207.5m)
|
|
Gross Profit
|
|
$37.2m
|
$48.2m
|
$60.0m
|
$88.3m
|
$141.5m
|
$193.0m
|
|
Operating Income (Loss)
|
|
($2.2m)
|
($22.5m)
|
($34.0m)
|
($12.4m)
|
$3.1m
|
$37.6m
|
|
Share of losses of equity method investees
|
|
$0
|
($538k)
|
($1.8m)
|
($1.6m)
|
($1.3m)
|
($226k)
|
|
Financial Income
|
|
—
|
—
|
$438k
|
$2.5m
|
$3.4m
|
$10.7m
|
|
Profit (loss) before taxes on income
|
|
($6.1m)
|
($24.1m)
|
($37.1m)
|
($14.7m)
|
($4.4m)
|
$34.6m
|
|
Profit (loss) for the period
|
|
($6.1m)
|
($24.8m)
|
($37.5m)
|
($15.9m)
|
($5.6m)
|
$35.5m
|
|
Basic earnings (loss) per share
|
|
($0.25)
|
($0.82)
|
($1.14)
|
($0.48)
|
($0.16)
|
$0.96
|
|
Diluted earnings (loss) per share
|
|
($0.25)
|
($0.82)
|
($1.14)
|
($0.48)
|
($0.16)
|
$0.94
|
|
Research and development expenses
|
|
($9.3m)
|
($19.0m)
|
($22.1m)
|
($21.9m)
|
($25.4m)
|
($30.0m)
|
|
Selling, general and administrative expenses
|
|
($26.5m)
|
($45.4m)
|
($64.1m)
|
($70.3m)
|
($98.2m)
|
($121.3m)
|
|
Depreciation and amortization in respect of technology and capitalized development costs
|
|
($3.6m)
|
($3.8m)
|
($4.3m)
|
($6.4m)
|
($11.6m)
|
($14.2m)
|
|
Other income (expenses)
|
|
$0
|
($1.9m)
|
($1.8m)
|
($444k)
|
($2.0m)
|
$10.3m
|
|
Financial Expense
|
|
—
|
—
|
($3.5m)
|
($4.8m)
|
($10.9m)
|
($13.7m)
|
|
Tax benefits (expenses)
|
|
$15k
|
($632k)
|
($451k)
|
($1.2m)
|
($1.2m)
|
$950k
|